Characteristics of trials in adults included in the review
| Study (year) | Design | Language and country | Jadad score | No (and age) >of patients | Mean baseline severity | Dose of >β agonist | Dose of anticholinergic | CCS use |
|---|---|---|---|---|---|---|---|---|
| MC, multicentre; TC, two centre; R, randomised; SB, single blind; DB, double blind; E, English; Sp, Spanish; FEV1, forced expiratory volume in 1 second; PEF, peak expiratory flow; S, salbutamol; F, fenoterol; IB, ipratropium bromide; OB, oxitropium bromide; Gly, glycopyrrolate; CCS, systemic corticosteroids. | ||||||||
| Bryant (1985)28 | R, DB | E, Australia | 2 | 28 (⩾18 y) | FEV1 <75% | F, 1 mg Neb ×1 | IB, 0.5 mg Neb ×1 | No |
| Rebuck et al (1987)29 | MC, R, DB | E, Canada | 4 | 148 (⩾18 y) | FEV1 <70% | F, 1.25 mg Neb ×1 | IB, 0.5 mg Neb ×1 | Yes |
| Higgins et al (1988)30 | R, DB | E, England | 2 | 40 (⩾18 y) | PEF <30% | S, 5 mg q120 min Neb ×2 | IB, 0.5 mg q120 min Neb ×2 | Yes |
| O’Driscoll et al (1989)31 | R, DB | E, England | 2 | 56 (⩾18 y) | PEF <35% | S, 10 mg Neb ×1 | IB, 0.5 mg Neb ×1 | Yes |
| Summers and Tarala (1990)32 | R, DB | E, Australia | 3 | 76 (16–70 y) | PEF <60% | S, 5 mg Neb ×1 | IB, 0.5 mg Neb ×1 | Yes |
| Cydulka and Emerman (1994)33 | R, DB | E, USA | 3 | 125 (⩾18 y) | FEV1 <75% | S, 2.5 mg q60 min Neb ×3 | Gly, 2 mg Neb ×1 | Yes |
| Rodrigo and Rodrigo (1995)34 | R, DB | Sp, Uruguay | 3 | 22 (18–50 y) | FEV1 <50% | S, 0.4 mg q10 min MDI ×3 h | IB, 0.08 mg q10 min MDI ×3 h | No |
| Karpel et al (1996)35 | MC, R, DB | E, USA | 5 | 384 (18–55 y) | FEV1 <60% | S, 2.5 mg q45 min Neb ×2 | IB, 0.5 mg q45 min Neb ×2 | No |
| FitzGerald et al >(1997)36 | MC, R, DB | E, Canada | 3 | 342 (18–50 y) | FEV1 <70% | S, 3 mg Neb ×1 | IB, 0.5 mg Neb ×1 | Yes |
| Garret et al (1997)37 | TC, R, DB | E, New Zealand | 4 | 338 (18–55 y) | FEV1 <70% | S, 2.5 mg q45 min Neb ×2 | IB, 0.5 mg q45 min Neb ×2 | Yes |
| Lin et al (1998)38 | R, DB | E, USA | 4 | 55 (⩾18 y) | PEF <200 l/min | S, 2.5 mg q20 min Neb ×3 | IB, 0.5 mg Neb ×1 | No |
| Kamei et al (1999)39 | MC, R | E, Japan | 3 | 64 (⩾18 y) | FEV1 <70% | F, 0.2 mg q1 min MDI ×5 | OB, 0.1 mg q1 min MDI ×5 | Yes |
| Weber et al (1999)40 | R, DB | E, USA | 5 | 67 (⩾18 y) | PEF <70% | S, 10 mg q1 h Neb ×3 h | IB, 1 mg q1 h Neb ×3 h | No |
| Nakano et al (2000)41 | R, SB | E, Japan | 4 | 74 (⩾18 y) | PEF <50% | S, 0.4 mg q20 min MDI ×3 | OB, 0.4 mg q20 min MDI ×3 | Yes |
| Rodrigo and Rodrigo (2000)42 | R, DB | E, Uruguay | 5 | 180 (18–50 y) | FEV1 <50% | S, 0.4 mg q10 min MDI ×3 h | IB, 0.08 mg q10 min MDI ×3 h | No |
| Aggarwal et al >(2002)43 | R | E, India | 2 | 48 (13–50 y) | PEF <50% | S, 5 mg q60 min Neb ×2 | IB, 0.5 mg Neb ×1 | No |